Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

# An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica

## Abstract

The aim of the study was to investigate the presence of subclinical vascular damage in polymyalgia rheumatica (PMR). We enrolled PMR patients having major cardiovascular risk factors (MCVRF) and, as controls, patients with MCVRF. All underwent: color Doppler ultrasound to evaluate the common carotid intima-media thickness (IMT), the anterior–posterior abdominal aortic diameter (APAD), and the prevalence of carotid artery stenosis; the cardio-ankle vascular index (CAVI) to measure arterial stiffness together with the ankle-brachial index (ABI) to investigate the presence of lower-extremity peripheral arterial disease. Finally, we measured the serum levels of adipocytokines implicated in vascular dysfunction. As a result, 48 PMR and 56 MCVRF patients were included. An increase of IMT (1.07/0.8–1.2 vs 0.8/0.8–1.05; p = 0.0001), CAVI (8.7/7.8–9.3 vs 7.6/6.9–7.8; p < 0.0001) and APAD values (21.15/18.1–25.6 vs 18/16–22; p = 0.0013) was found in PMR patients with respect to controls. No differences were reported in the prevalence of carotid artery stenosis or ABI values between the two groups. A significant correlation between IMT and CAVI in PMR and MCVRF subjects (r2 = 0.845 and r2 = 0.556, respectively; p < 0.01) was found. Leptin levels (pg/mL; median/25th–75th percentile) were higher in PMR than in MCVRF subjects (145.1/67–398.6 vs 59.5/39.3–194.3; p = 0.04). Serum levels of adiponectin (ng/mL) were higher in PMR patients (15.9/10.65–24.1 vs 6.1/2.8–22.7; p = 0.01), while no difference in serum levels of resistin (ng/mL) was found between PMR and MCVRF subjects (0.37/0.16–0.66 vs 0.26/0.14–1.24). Our study shows an increased subclinical vascular damage in PMR patients compared to those with MCVRF, paving the way for further studies aimed at planning primary cardiovascular prevention in this population.

## Introduction

The association of chronic inflammatory rheumatic disorders such as rheumatoid arthritis (RA), spondyloarthritis, gout, systemic lupus erythematosus (SLE), and scleroderma with an increased risk of vascular disease, especially cardiovascular and cerebrovascular disease, is a consolidated matter1,2,3,4,5,6,7,8. Polymyalgia rheumatica (PMR) is a chronic, inflammatory disorder occurring in individuals at the age of 50 years or older, characterized by aching and stiffness in the proximal regions of the extremities as well as elevated markers of inflammation9. Incidence increases with age, peaks between 70 and 80 years, and is greater in women that are affected 2–3 times more frequently than men9. PMR has been associated, both in men and women, with a 2.6 increased risk for vascular events, including cardiovascular, cerebrovascular, and peripheral vascular events10. While in patients with RA and SLE the greatest cardiovascular risk occurs in established disease, in PMR the excess risk was seen both early in the disease and throughout the follow-up period11. The relevance of this issue is further supported by the observation that cardiovascular comorbidities in patients with PMR were mainly responsible for an increase in direct medical costs compared to age- and sex-matched controls from the same community in a Minnesota County12. However, a systematic review found inconsistent results, with some studies reporting a positive association and others no association between PMR and vascular disease13.

The aim of our study was to investigate the presence of subclinical vascular damage in patients with PMR through a validated and non-invasive approach, including the common carotid intima-media thickness (IMT) assessment14 and the cardio-ankle vascular index (CAVI), a method for estimating arterial stiffness and predicting cardiovascular risk developed by measuring pulse wave velocity (PWV) and blood pressure15.

## Methods

### Data source and study cohort

Between May 2017 and May 2018, consecutive Caucasian patients with PMR according to the EULAR classification criteria16 also having major cardiovascular risk factors (MCVRF), including hypertension, diabetes, hypercholesterolemia, cigarette smoking, and obesity, were recruited from the Rheumatology Unit at Sapienza University of Rome, Rome, Italy. As controls, consecutive Caucasian patients with MCVRF were enrolled at the Angiology Unit at Sapienza University of Rome, Rome, Italy, as long as a PMR diagnosis had been excluded.

At recruitment, data on demographics, disease duration, treatments (with particular focus on glucocorticoids for PMR patients) were obtained by direct questioning and collected in a computerized form. Hypertension was defined as values ≥ 140 mmHg systolic blood pressure (SBP) and/or ≥ 90 mmHg diastolic blood pressure (DBP) according to the criteria published in 2013 by the European Society of Hypertension (ESH) and European Society of Cardiology (ESC)17. Diabetes was defined on the basis of fasting plasma glucose levels ≥ 126 mg/dL on 2 separate occasions18 or the use of anti-diabetic drugs. In accordance with the 2013 American College of Cardiology/American Heart Association Guidelines (ACC/AHA), hypercholesterolemia was defined as total cholesterol ≥ 220 mg/dL or the use of lipid-lowering drugs19. Finally, obesity was defined as a body mass index (BMI) of 30 kg/m2 or above20. All patients had a color Doppler ultrasound assessment and a CAVI measurement. We also analyzed the serum levels of adipocytokines known to be implicated in vascular dysfunction21.

This study was conducted in accordance with the Declaration of Helsinki, and informed consent was obtained from all the patients. The study design was approved by the Ethical Committee of Sapienza University of Rome, Rome, Italy (reference number 4625, protocol 729/17).

### Color Doppler ultrasound assessment

The measurement of common carotid artery IMT is a well-established cardiovascular risk marker, being both a measure of early atherosclerosis and of smooth muscle hypertrophy/hyperplasia22. Mannheim Carotid IMT Consensus (2004–2006) established guidelines for IMT assessment and distinction between IMT and atherosclerotic plaque by ultrasound based on localization, natural history, risk factors and predictive value for vascular events14.

In all patients we performed a two-dimensional echo color Doppler ultrasound of the common carotid arteries, adopting a high definition vascular echograph (Esaote MyLab 50 X-Vision) in order to detect the IMT and the prevalence of carotid stenosis. Carotid artery color Doppler ultrasound was performed by a 7.5 MHz linear transducer, using an overhead technique, with the examiner seated behind the patient’s head. The patient was positioned supine, with its head slightly extended backwards and turned opposite to the side of interrogation. The degree of carotid artery stenosis, where present, was measured according to the European Carotid Surgery Trial (ECST) criteria23. Furthermore, we carried out ultrasound imaging of anterior–posterior abdominal aortic diameter (APAD) to screen for abdominal aortic aneurysm occurrence. Abdominal aorta was assessed by a 3.5 MHz convex transducer in longitudinal and transverse planes from the level of the diaphragm to the bifurcation. Aneurysm was defined as infrarenal arterial enlargement with a maximum diameter ≥ 30 mm associated to loss of arterial wall parallelism24.

### Cardio-ankle vascular index

Since arterial stiffness has been associated with atherosclerosis, we also studied patients by CAVI, a blood pressure-independent index that measures the stiffness of the aorta, femoral artery and tibial artery. CAVI is calculated using the formula below enriched with measurements from an electrocardiogram, phonocardiogram, brachial artery waveform, and ankle artery waveform15:

$$CAVI = {\alpha} = {\left( {{2{\text{\th}}}/\Delta {{P}}} \right) x {{ ln }}\left( {{{SBP}}/{{DBP}}} \right){{ PWV^2}}} \, + \beta$$

where ∆P is SBP–DBP, þ is blood density, PWV is pulse wave velocity (another measure of arterial stiffness), and a and β are constants. Scale conversion constants are determined so as to match CAVI with PWV using Hasegawa’s method. All measurements and calculations are made together and automatically in VaSera (Fukuda Denshi Co. Ltd. Tokyo, Japan). This equation was derived from Bramwell-Hill’s formula and the stiffness parameter β. CAVI uses blood pressure cuffs with sensors on all four limbs to generate plethysmographs. The cuffs are placed on bilateral upper and lower extremities while the patient is in supine position with the limbs at the same level as the heart, in a comfortable position in a warm room. Measurement of ankle-brachial index (ABI), a tool to assess the presence of lower-extremity peripheral arterial disease17, was performed during CAVI measurement. Report from the instrument used for CAVI measurement included ABI index value as an output data. ABI was calculated directly by the instrument by using superior and inferior limb systolic pressure measurement. The mean bilateral (right/left side) CAVI and ABI values were used in our analysis.

The serum levels of leptin, adiponectin, and resistin were measured in PMR patients and controls. Venous blood samples were taken after 12 h of nocturnal fasting, then centrifuged and the serum stored at − 35 °C until analysis was performed by using a commercial ELISA according to the manufacturer’s instructions (Invitrogen Thermo Fisher Scientific, Camarillo, CA, USA).

### Statistical analysis

Descriptive statistics [mean, standard deviation (SD); median 25th–75th percentile] were used to present quantitative variables, whereas percentages and frequencies were generated for qualitative variables. Differences between patients with PMR and MCVRF controls were tested using Student’s t test or Mann–Whitney test when appropriate and χ2 test for quantitative and categorical variables, respectively. Bivariate analysis was conducted using the Pearson rho coefficient and Spearman correlation coefficient for quantitative variables. The statistical analysis was carried out using SPSS, release 23.0 (SPSS, Inc., Chicago, IL, USA). The statistical significance was set at p < 0.05. A sample size of at least 18 patients per group was estimated for 80% power by assuming a 5% significance level and considering a 2.6 relative risk for vascular events associated with PMR10 and a 50% prevalence of cardiovascular disease in the general population.

## Results

### Cohort characteristics

Forty-eight patients with PMR and 56 with MCVRF were included in the study. The main demographic and clinical data are shown in Table 1. No significant differences between the 2 groups with respect to gender, age, and prevalence of MCVRF were found, except for SBP which was significantly higher in patients with PMR (p = 0.03). When appropriate, patients were in pharmacological treatment (anti-hypertensive drugs, anti-diabetic drugs, lipid-lowering drugs) for their own cardiovascular risk factors.

### Color Doppler ultrasound assessment and CAVI

A significant increase of IMT values (median/25th–75th percentile) was found in PMR compared to MCVRF controls (1.07/0.8–1.2 vs 0.8/0.8–1.05; p = 0.0001) (Fig. 1). Likewise, mean CAVI values (median/25th–75th percentile) were higher in patients with PMR than MCVRF controls (8.7/7.8–9.3 vs 7.6/6.9–7.8; p < 0.0001) (Fig. 2).

When we evaluated APAD for occurrence of abdominal aortic aneurysm, we found an increased value (median/25th–75th percentile) in patients with PMR compared to MCVRF controls (21.15/18.1–25.6 vs 18/16–22; p = 0.0013), in the absence of aortic aneurysm (Fig. 3). No differences were reported with regards to the prevalence of carotid artery stenosis or ABI values between the two groups. In our study, no patient had an ABI value < 0.9, which would have been an exclusion criterion being potentially responsible for unreliable CAVI values15. No significant correlation between disease duration or mean glucocorticoid daily dosage and IMT or CAVI values was found in PMR patients. Finally, the results of the bivariate regression analysis showed a positive correlation between IMT and CAVI values in both PMR patients and MCVRF subjects ($${r}^{2}$$=0.845 and $${r}^{2}$$=0.556, respectively; p < 0.01) (Fig. 4).

Serum levels of leptin, adiponectin, and resistin were measured in 40 patients with PMR and in 17 MCVRF controls. Leptin levels (pg/mL; median/25th–75th percentile) were higher in patients with PMR than in MCVRF subjects (145.1/67–398.6 vs 59.5/39.3–194.3; p = 0.04). Likewise, serum levels of adiponectin (ng/mL) were higher in patients with PMR (15.9/10.65–24.1 vs 6.1/2.8–22.7; p = 0.01) (Fig. 5), while no difference in serum levels of resistin (ng/mL) was found between PMR and MCVRF subjects (0.37/0.16–0.66 vs 0.26/0.14–1.24) (not shown). No correlation was found analyzing serum adipocytokine levels with each other or with the clinical and laboratory parameters of PMR patients and MCVRF subjects.

## Discussion

The high prevalence of traditional cardiovascular risk factors together with the burden of the systemic inflammatory response sustains the increased cardiovascular risk in chronic inflammatory rheumatic diseases1,2,3,4,5,6,7,8.

Although a systematic review found inconsistent results with respect to the increased vascular damage in PMR13, some studies do support this item10,25. Analyzing the electronic database of primary care physicians in England and Wales, a 2.6 relative risk for cardiovascular disease in PMR patients with respect to the general population was reported over a median follow-up period of 7.8 years. In particular, the relative risk was found to be 2.7 for cardioischemic disease, 2.3 for cerebrovascular disease, and 2.8 for peripheral artery disease10. Furthermore, a meta-analysis of observational high-quality studies that included 34,569 patients with PMR showed a 72% excess risk of coronary artery disease among patients with PMR compared with subjects without PMR, even if the statistical heterogeneity of the reviewed studies was high26. Conversely, in a recent study, patients with PMR or GCA did not have a high risk for cardiovascular disease, but we must remark that the setting was Japan population, having the lowest incidence of PMR in the world and milder symptoms than in the Western countries27.

The association of PMR with vascular disease may be explained by the elevated levels of C-reactive protein, which is also one of the independent biomarkers associated with cardiovascular disease28. Furthermore, vascular inflammation was demonstrated in most patients with PMR by 18F-FDG PET/CT imaging, showing an increased 18F-FDG uptake mainly in the aorta and its major branches24,29. This finding implies, even in PMR patients without clinical signs of vasculitis such as stenosis or aneurysm, possible subclinical inflammatory lesions on arteries. Interestingly, we found significantly increased values of APAD in the absence of abdominal aortic aneurysm in our patients with PMR, who did not have clinically overt giant cell arteritis, compared to MCVRF controls.

This assessment was part of our study, aimed at assessing the subclinical vascular involvement in PMR patients, in order to obtain data that could eventually suggest the need for planning primary cardiovascular prevention. We performed color Doppler ultrasound to evaluate, in addition to APAD, carotid IMT and carotid artery stenosis; we also assessed CAVI to measure arterial stiffness parameters and ABI. These are considered appropriate tools for detecting asymptomatic organ damage in the context of overall cardiovascular risk due to their non-invasiveness, availability, suitability for outpatients, repeatability and low cost17. IMT significantly predicts plaque occurrence14 and serves as a proxy of generalized atherosclerosis when a value of > 0.9 mm is found17. In PMR patients we observed a significant increase of carotid IMT with respect to controls and, notably, the mean IMT was superior to the 0.9 mm cut-off. Since IMT is a critical marker of increased risk of vascular events, this finding is consistent with the results of previous studies10,25 and supports further attention on the risk of cardiovascular disease in PMR. Another parameter for evaluating cardiovascular risk is the arterial stiffness, traditionally assessed in terms of carotid-femoral PWV. Its correlations with carotid IMT, carotid stenosis, aortic and peripheral atherosclerosis have been proved30. We decided to investigate this parameter by using an alternative tool, i.e. CAVI, a non-invasive and a blood pressure-independent technique which can be used to estimate the risk of atherosclerosis31. Not only our PMR patients had greater mean CAVI score than controls, but also showed a positive correlation with carotid IMT, confirming the potential of CAVI as a useful and reliable cardiovascular risk marker. A similar correlation was found in MCVRF patients. Consistent with these results, CAVI score was positively correlated with the carotid IMT in patients with hypertension32, type 2 diabetes mellitus33, coronary artery disease34, in those with moderate cardiovascular risk31, and in the general population35.

Glucocorticoids are the recommended first-line treatment in PMR, but their role in promoting an increased cardiovascular risk is controversial. Potential side effects of glucocorticoids, including hypertension, hyperlipidemia, and diabetes mellitus may indeed participate in this adverse outcome36. On the other hand, glucocorticoids may decrease the vascular risk in patients with PMR by suppressing inflammation37. In fact, a decrease of aortic PWV after prednisone treatment was found in patients with PMR38. Accordingly, in our patients neither we found any significant correlation between the mean daily dosage of glucocorticoids (evaluated at the time of the study) and carotid IMT or CAVI values nor between the mean cumulative dosage of glucocorticoids and carotid IMT or CAVI values.

Finally, we measured serum levels of adipocytokines, which are considered biomarkers of cardiovascular risk since their levels are increased in patients with metabolic syndrome, insulin resistance, and obesity39. Leptin and resistin showed pro-atherogenic effects under experimental conditions, whereas adiponectin seems to have both anti- and pro-inflammatory activity, probably explained by its different isoform40. In RA patients, adiponectin showed critical pro-inflammatory properties, being elevated in serum and synovial fluid, strongly expressed at the synovium level, and directly correlating with disease activity and radiologic progression41. Similarly, in our PMR patients we observed significantly higher serum levels of leptin and adiponectin compared to MCVRF controls, which parallels the increased cardiovascular risk demonstrated by ultrasound and CAVI, although no correlation was found with clinical and laboratory features of the patients. Serum levels of leptin and adiponectin had been previously investigated in two studies including a small number of PMR patients, where a significant increase was observed after treatment with glucocorticoids42,43. Conversely, glucocorticoids are able to reduce serum levels of resistin, as shown in a small number of patients with systemic autoimmune diseases44. Indeed, unlike leptin and adiponectin, resistin is mainly produced by bone marrow-derived mononuclear cells with some contribution from adipocytes45. It is conceivable that we did not observe any difference in serum levels of resistin between PMR and MCVRF probably due to the effect of glucocorticoid therapy in patients with PMR.

The main limitation of our study is represented by the cross-sectional design, which does not help to establish a cause-effect ratio between inflammation and vascular lesions. In such a design, the timing of the snapshot does not assure to be representative and a longitudinal follow-up should be prompted to support the data.

In conclusion, we evaluated for the first time the presence of subclinical vascular damage in patients with PMR. Our results show an increase in subclinical cardiovascular lesions with respect to patients with MCVRF, paving the way for further studies aimed at planning primary cardiovascular prevention in PMR patients. If our data will be confirmed in longitudinal studies, the cardiovascular risk profile should be considered as part of the overall management of PMR patients by using validated algorithms which may suggest lifestyle changes and additional treatments.

## Data availability

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

## References

1. Liao, K. P. et al. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 52, 45–52 (2013).

2. Bremander, A. et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. (Hoboken) 63, 550–556 (2011).

3. Essers, I. et al. Ankylosing spondylitis and risk of ischaemic heart disease: A population-based cohort study. Ann. Rheum. Dis. 75, 203–209 (2016).

4. Haroon, N. N. et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: A population-based study. Ann. Intern. Med. 163, 409–416 (2015).

5. Jafri, K. et al. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based study. Arthritis Care Res. (Hoboken) 69, 51–57 (2017).

6. Clarson, L. et al. Increased cardiovascular mortality associated with gout: A systematic review and meta-analysis. Eur. J. Prev. Cardiol. 22, 335–343 (2015).

7. Benvenuti, F. et al. Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: A literature review. Expert. Opin. Drug Saf. 14, 1373–1385 (2015).

8. Nordin, A. et al. Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: A population-based case–control study. Arthritis Res. Ther. 15, R87 (2013).

9. González-Gay, M. A. et al. Polymyalgia rheumatica. Lancet 390, 1700–1712 (2017).

10. Hancock, A. T. et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ 186, E495-501 (2014).

11. Avina-Zubieta, J. A. et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524–1529 (2012).

12. Kremers, H. M. et al. Direct medical cost of polymyalgia rheumatica. Arthritis Rheum. 53, 578–584 (2005).

13. Hancock, A. T. et al. Association between polymyalgia rheumatica and vascular disease: A systematic review. Arthritis Care Res. (Hoboken) 64, 1301–1305 (2012).

14. Touboul, P. J. et al. Cerebrovasc Dis 34, 290–296 (2012).

15. Shirai, K. et al. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J. Atheroscler. Thromb. 13, 101–107 (2006).

16. Dasgupta, B. et al. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 64, 943–954 (2012).

17. Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart. J. 34, 2159–2219 (2013).

18. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 35(Suppl 1), S11-63 (2012).

19. Smith, S. C. Jr. et al. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J. Am. Coll. Cardiol. 64, 601–612 (2014).

20. Eknoyan, G. Adolphe Quetelet (1796–1874)—the average man and indices of obesity. Nephrol. Dial. Transplant. 23, 47–51 (2008).

21. Ouwens, D. M. et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J. Cell Mol. Med. 14, 2223–2234 (2010).

22. Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 252, 207–274 (2016).

23. ECST Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351, 1379–1387 (1998).

24. Erbel, R. et al. ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2873–2926 (2014).

25. Lavado-Pérez, C. et al. (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. Rev. Esp. Med. Nucl. Imagen Mol. 34, 275–281 (2015).

26. Ungprasert, P. et al. Polymyalgia rheumatica and risk of coronary artery disease: A systematic review and meta-analysis of observational studies. Rheumatol. Int. 37, 143–149 (2017).

27. Kobayashi, D. et al. Incidence of cardiovascular events in polymyalgia rheumatica and giant cell arteritis amongst an Asian population: Propensity score matched cohort study. Int. J. Rheum. Dis. 21, 1314–1321 (2018).

28. Okazaki, S. et al. Association of inflammatory markers and carotid intima-media thickness with the risk of cardiovascular events in high-risk patients. Cerebrovasc. Dis. 30, 180–187 (2010).

29. Moosig, F. et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: A quantitative PET study. Ann. Rheum. Dis. 63, 870–873 (2004).

30. van Popele, N. M. et al. Association between arterial stiffness and atherosclerosis: The Rotterdam Study. Stroke 32, 454–460 (2001).

31. Gomez-Sanchez, L. et al. The association between the cardio-ankle vascular index and other parameters of vascular structure and function in Caucasian adults: MARK study. J. Atheroscler. Thromb. 22, 901–911 (2015).

32. Okura, T. et al. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens. Res. 30, 335–340 (2007).

33. Gómez-Marcos, M. Á et al. Cardio-ankle vascular index is associated with cardiovascular target organ damage and vascular structure and function in patients with diabetes or metabolic syndrome, LOD-DIABETES study: A case series report. Cardiovasc. Diabetol. 14, 7 (2015).

34. Nakamura, K. et al. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ. J. 72, 598–604 (2008).

35. Kadota, K. et al. Availability of cardio-ankle vascular index (CAVI) as a screening tool for atherosclerosis. Circ. J. 72, 304–308 (2008).

36. Gabriel, S. E. et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis. Rheum. 40, 1873–1878 (1997).

37. MaraditKremers, H. et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum. 57, 279–286 (2007).

38. Schillaci, G. et al. Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. Ann. Rheum. Dis. 71, 1151–1156 (2012).

39. Abella, V. et al. Adipokines, metabolic syndrome and rheumatic diseases. J. Immunol. Res. 2014, 343746 (2014).

40. Scrivo, R. et al. Rheumatic diseases and obesity: Adipocytokines as potential comorbidity biomarkers for cardiovascular diseases. Mediators Inflamm. 2013, 808125 (2013).

41. Frommer, K. W. et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum. 62, 2886–2899 (2010).

42. Cimmino, M. A. et al. Changes in adiponectin and leptin concentrations during glucocorticoid treatment: A pilot study in patients with polymyalgia rheumatica. Ann. N Y Acad. Sci. 1193, 160–163 (2010).

43. Kreiner, F. et al. Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rheumatica. Scand. J. Rheumatol. 39, 402–408 (2010).

44. Tanaka, N. et al. Serum resistin level and progression of atherosclerosis during glucocorticoid therapy for systemic autoimmune diseases. Metabolites 6, 3 (2016).

45. Hutcheson, J. Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75, 272–279 (2015).

## Acknowledgements

This work was supported by Progetti di Ricerca d’Ateneo 2016, Sapienza University of Rome, Rome, Italy.

## Author information

Authors

### Contributions

R.S., V.S. and F.C. designed the research study. F.C., P.S., I.R. and C.B. performed the research. F.C., A.A., C.A., F.C., M.D.F., R.P., V.R., A.S.S. and F.R.S enrolled the subjects. C.S. and G.L.T. performed statistical analysis. R.S. and V.S. wrote the paper. L.A., F.F., B.G., F.C. and G.V. revised the paper. All have read and agreed to publication of the manuscript.

### Corresponding author

Correspondence to Rossana Scrivo.

## Ethics declarations

### Competing interests

The authors declare no competing interests.

### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Scrivo, R., Silvestri, V., Ciciarello, F. et al. An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica. Sci Rep 10, 11407 (2020). https://doi.org/10.1038/s41598-020-68215-8

• Accepted:

• Published:

• DOI: https://doi.org/10.1038/s41598-020-68215-8

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.